| Drug Name |
Dactinomycin |
| Drug ID |
BADD_D00571 |
| Description |
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) |
| Indications and Usage |
For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen |
| Marketing Status |
approved; investigational |
| ATC Code |
L01DA01 |
| DrugBank ID |
DB00970
|
| KEGG ID |
D00214
|
| MeSH ID |
D003609
|
| PubChem ID |
457193
|
| TTD Drug ID |
D0P8IV
|
| NDC Product Code |
58623-0098; 68305-200; 66993-489; 71288-129; 68254-0017; 55292-811; 55150-431; 42658-008; 55150-928; 39822-2100 |
| UNII |
1CC1JFE158
|
| Synonyms |
Dactinomycin | Meractinomycin | Actinomycin D | Actinomycin | Cosmegen | Cosmegen Lyovac | Lyovac, Cosmegen | Lyovac-Cosmegen | Lyovac Cosmegen | LyovacCosmegen |
